10.08.2018 Carl Zeiss Meditec AG  DE0005313704

DGAP-News: Carl Zeiss Meditec accelerates growth

DGAP-News: Carl Zeiss Meditec AG / Key word(s): 9-month figures Carl Zeiss Meditec accelerates growth 10.08.2018 / 06:55 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Carl Zeiss Meditec accelerates growth Positive contributions from both strategic business units and from all regions JENA, 10 August 2018 After nine months 2017/18, Carl Zeiss Meditec AG was able to achieve further encouraging growth in all strategic business units and regions: Revenue increased by 7.1 percent (adjusted for currency effects, 11.7 percent), to EUR926.3m (prior year: EUR864.7m). Earnings before interest and taxes (EBIT) rose slightly, to EUR134.8m (prior year: EUR132.6m). The adjusted EBIT margin remained stable at 14.8 percent (prior year: 14.7 percent). Earnings per share reached EUR0.92 (prior year: EUR1.10). "As already announced in early July, given the positive revenue growth in the third quarter, the revenue forecast for fiscal year 2017/18 was increased slightly to EUR1,250m - EUR1,300m. I am particularly pleased that both Strategic Business Units and all regions once again contributed significantly to this. The positive development of our latest product innovations validates our strategy to further drive forward the development of innovative solutions in the medical sector and to further expand our global orientation," said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG, commenting on the result. Solid growth in both strategic business units The Ophthalmic Devices strategic business unit (SBU) increased its revenue by 6.4 percent in the first nine months of the current fiscal year (adjusted for currency effects: 10.7 percent), to EUR681.0m, compared with EUR639.9m in the same period of the prior year. The laser systems business for refractive vision correction and diagnostic instruments developed particularly well. There was also continued solid demand for intraocular lenses for the treatment of cataracts. Revenue in the Microsurgery SBU grew by 9.1 percent (adjusted for currency effects: 14.3 percent). Revenue from surgical microscopes and visualization solutions climbed to EUR245.2m, compared with EUR224.8m in the prior year. This was particularly due to the new KINEVO 900 visualization system for neurosurgeons. Strong organic growth in all regions Revenue in the EMEA region increased by 8.6 percent (adjusted for currency effects: 10.0 percent) to almost EUR282.0m (prior year: EUR259.6m). This increase was attributable to the stable development in the core markets Germany and France, and to solid growth in the UK and Southern Europe. On a currency adjusted basis, revenue in the Americas region grew by 11.7 percent to EUR279.3m (prior year: EUR272.5m). Due to negative currency effects, reported revenue only grew slightly by 2.5 percent year-on-year. The positive trend in the US market continued. The Asia/Pacific region (APAC) grew by 9.7 percent, to EUR364.9m (prior year: EUR332.6m). After adjustment for currency effects, this corresponds to an increase of 13.0 percent. The largest contributions to growth came from China and South Korea. Earnings per share declined to EUR0.92 (prior year: EUR1.10). It was, however, predominantly non-operating factors that contributed to this, specifically the one-time proceeds from the sale of non-strategic assets in the prior year, a negative currency result and the increase in the number of outstanding shares following the capital increase in March 2017. Carl Zeiss Meditec confirms its revenue projections for fiscal year 2017/18 as published in the ad hoc disclosure dated 3 July 2018. Revenue is expected to be within the range of EUR1,250m - EUR1,300m (previously: EUR1,230m - EUR1,280m). The EBIT margin is expected to remain within the range of 14 percent to 16 percent on an adjusted basis. Revenue by strategic business unit All 9 months 9 months Change from Change from prior year figures 2017/18 2016/17 prior year (adjusted for currency in EURm effects) Ophthalmi- 681.0 639.9 +6.4% +10.7% c Devices Microsurg- 245.2 224.8 +9.1% +14.3% ery Total 926.3 864.7 +7.1% +11.7% Revenue by region All 9 months 9 months Change from Change from prior year figures 2017/18 2016/17 prior year (adjusted for currency in EURm effects) EMEA 282.0 259.6 +8.6% +10.0% Americas 279.3 272.5 +2.5% +11.7% APAC 364.9 332.6 +9.7% +13.0% Total 926.3 864.7 +7.1% +11.7% Contact for investors and press Sebastian Frericks Director Investor Relations Carl Zeiss Meditec AG Phone: +49 (0)3641 220-116 Email: [email protected] www.zeiss.com/press --------------------------------------------------------------------------- 10.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Carl Zeiss Meditec AG Göschwitzer Str. 51-52 07745 Jena Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: [email protected] Internet: www.zeiss.de/meditec-ag/ir ISIN: DE0005313704 WKN: 531370 Indices: TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 712919 10.08.2018

Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 1.088,37 1.189,90 1.280,86 1.459,32 1.335,45 1.646,79 1.710,00
EBITDA1,2 174,56 205,07 228,41 313,03 237,98 435,20 407,50
EBITDA-Marge3 16,04 17,23 17,83 21,45 17,82 26,43 23,83
EBIT1,4 154,33 180,83 197,13 264,66 177,55 373,61 344,00
EBIT-Marge5 14,18 15,20 15,39 18,14 13,30 22,69 20,12
Jahresüberschuss1 99,97 135,78 126,23 160,58 123,42 237,52 221,00
Netto-Marge6 9,19 11,41 9,86 11,00 9,24 14,42 12,92
Cashflow1,7 111,77 37,73 187,21 219,63 178,53 362,66 0,00
Ergebnis je Aktie8 1,21 1,57 1,41 1,79 1,37 2,64 2,42
Dividende8 0,42 0,55 0,55 0,65 0,50 0,90 0,90
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Ernst & Young

XETR:AFX Charts by TradingView (c)

Carl Zeiss Meditec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
531370 141,950 Halten 12.696,09
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
45,06 31,92 1,46 93,28
8,04 35,01 7,71 27,01
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
0,50 0,90 0,63 30.03.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
11.02.2022 13.05.2022 05.08.2022 10.12.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-18,61% -16,36% -23,21% 10,90%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Carl Zeiss Meditec AG  ISIN: DE0005313704 können Sie bei DGAP abrufen

Medtech , 531370 , AFX , XETR:AFX